產(chǎn)品名稱：Capecitabine 產(chǎn)品貨號：LC C-2799 產(chǎn)品規(guī)格：10 G Capecitabine is a pre-prodrug of 5-fluorouracil (5-FU). After oral uptake, capecitabine is first metabolized to 5'-deoxy-5-fluorocytidine (5'-DFCR), which happens mainly in the liver by carboxyl-esterase. The metabolite is converted to 5'-deoxy-5-fluoro-uridine (5'-DFUR) by cytidine deaminase in liver and tumor tissue. Then 5'-DFUR is converted to 5-FU intracellularly by thymidine phosphorylase, which is often expressed in tumor tissue. Miwa, M., et al. "Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue." Eur. J. Cancer 34: 1274-1281 (1998). Capecitabine inhibits tumor growth by incorporation of 5-FU into RNA and DNA and inhibition of thymidylate synthase. Schellens, J.H. "Capecitabine." Oncologist 12: 152-155 (2007). Capecitabine is the active ingredient in the drug sold under the trade name Xeloda®. This drug has been approved in at least one country for use in patients with metastatic breast and colorectal cancers. NOTE: The capecitabine product sold by LC Laboratories is NOT Xeloda®, and is NOT for human use. Other CAS numbers previously assigned to capecitabine, 158798-73-3 and 958887-39-3, have been deleted by CAS and are no longer in use. We note that two of our competitors, International Laboratory and Advanced Technology, as of March 6, 2012, are claiming 99.9% purity for their Capecitabine. These claims are not credible in general chemical terms for this complex organic compound, nor in terms of the sensitivity and reproducibility of generally utilized analytical techniques. Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use./b>. This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries. Not available in some countries; not available to some institutions; not available for some uses. Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 100 mg/mL; soluble in ethanol at 12.5 mg/mL with slight warming; soluble in water at 2 mg/mL with slight warming; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A
滬公網(wǎng)安備 31011002002623號
